The efficacy and afety of latanoprot 0.005% once daily veru brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertenion

PURPOE: To evaluate the efficacy and afety of latanoprot 0.005% given topically every evening veru brimonidine 0.2% given topically twice daily in primary open-angle glaucoma or ocular hypertenive patient. METHOD: Thi wa a multicenter, croover, double-maked comparion. After a 28-day treatment-free period, patient with primary open-angle glaucoma or ocular hypertenion were randomized for 6 week to brimonidine or latanoprot and then croed over to the oppoite treatment. At baeline and after each treatment period, patient underwent intraocular preure meaurement every 2 hour from 08:00 to 20:00. REULT: In 33 patient the mean baeline trough (08:00) wa 23.2 ± 2.1 mm Hg and the diurnal curve preure wa 19.8 ± 2.7 mm Hg. The trough and diurnal intraocular preure for brimonidine were 19.6 ± 3.4 mm Hg and 17.6 ± 2.2 mm Hg, repectively. Brimonidine tatitically reduced the preure from baeline at each time point except hour 10 and 12 (P = .14 and P = .21, repectively). For latanoprot, the trough and diurnal preure were 16.2 ± 2.9 mm Hg and 15.4 ± 2.5 mm Hg, repectively, and the preure wa tatitically reduced at each time point (P < .001) and for the diurnal curve (P < .001). When compared directly, the intraocular preure level for latanoprot wa lower than brimonidine for the diurnal preure and at each time point (P < .05). One patient wa dicontinued early from latanoprot treatment becaue of eyelid welling; alo, latanoprot caued more hyperemia than brimonidine (P = .04). CONCLUION: Thi tudy ugget latanoprot doed daily in the evening tatitically reduce intraocular preure more during daytime and evening hour than brimonidine doed twice daily. Brimonidine may not conitently decreae the preure 10 and 12 hour pat doing from nontreated level